Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
CLEARMIND MEDICINE INC. |
End-of-day quote
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 5.17 CAD | -8.66% | +23.10% | -96.12% | |
| Sales 2022 * | - | Sales 2023 * | - | Capitalization | 10.95M 14.83M |
|---|---|---|---|---|---|
| Net income 2022 | -9M -12.19M | Net income 2023 * | - | EV / Sales 2022 | - |
| Net cash position 2022 | 388K 525K | Net cash position 2023 * | - 0 | EV / Sales 2023 * | - |
| P/E ratio 2022 | -1,15x | P/E ratio 2023 * | Employees | - | |
| Yield 2022 | - | Yield 2023 * |
-
| Free-Float | 90.66% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -8.66% | ||
| 1 week | +23.10% | ||
| Current month | +3.40% | ||
| 1 month | -9.30% | ||
| 3 months | -71.28% | ||
| 6 months | -76.39% | ||
| Current year | -96.12% |
1 week
3.61
8.00
1 month
3.618.00
Current year
3.61210.00
1 year
3.61218.10
3 years
3.61891.00
5 years
3.61891.00
10 years
3.61891.00
| Managers | Title | Age | Since |
|---|---|---|---|
Adi Zuloff-Shani
CEO | Chief Executive Officer | 53 | 2021 |
Alan Rootenberg
DFI | Director of Finance/CFO | 71 | 2019 |
Mark Haden
PRN | Corporate Officer/Principal | - | 2021 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alan Rootenberg
DFI | Director of Finance/CFO | 71 | 2019 |
Adi Zuloff-Shani
CEO | Chief Executive Officer | 53 | 2021 |
Amitay Weiss
CHM | Chairman | 61 | 2019 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.74% | 6 M€ | -23.66% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-04 | 5.17 | -8.66% | 7,724 |
| 23-12-01 | 5.66 | +13.20% | 31,301 |
| 23-11-30 | 5 | +20.48% | 15,690 |
| 23-11-29 | 4.15 | -6.74% | 5,021 |
| 23-11-28 | 4.45 | +5.95% | 9,788 |
End-of-day quote Canadian Securities Exchange, December 03, 2023
More quotes
Clearmind Medicine Inc. is a Canada-based psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Companyâs intellectual portfolio consists of fourteen patent families. The Company's portfolio consists of patent families, such as alcoholic beverage substitute and binge behaviour regulators.
Calendar
2024-02-26
- Q4 2023 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -96.12% | 3 M $ | |
| +65.85% | 40 132 M $ | |
| +5.55% | 39 586 M $ | |
| -55.53% | 30 438 M $ | |
| -27.15% | 28 571 M $ | |
| +37.25% | 22 175 M $ | |
| -27.26% | 21 511 M $ | |
| +1.31% | 17 412 M $ | |
| -13.72% | 11 313 M $ | |
| -7.93% | 10 346 M $ |
